evipedia.ai
← Back

Thymosin Alpha-1 for Health & Longevity

Created on 10/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Thymosin alpha-1, a natural hormone of the thymus (an immune gland), sold as a prescription injection in many countries but not approved in the United States, draws longevity interest for slowing immune aging. Its clearest benefit is stronger influenza vaccine responses in later life; no study has tested thymus renewal or lifespan in healthy people. Safety in trials looks largely reassuring, but quality of products sold outside pharmacies is uncertain. (Full Review)

Protocol

Healthy-aging use
1.6 mg twice weekly
No regimen tested in healthy adults; peptide clinics borrow the label dose as continuous multi-month courses or vaccine-timed pulses, neither shown superior
Vaccine-adjunct regimen
900 µg/m² twice weekly
Subcutaneous, eight doses, begun with influenza vaccination in men aged 65–99
Hepatitis B label regimen
1.6 mg twice weekly
About 900 µg/m² body surface area, subcutaneous, for 6–12 months
Time to effect
Vaccine antibody gains
3–6 weeks
After influenza vaccination in older men
Hepatitis B responses
6–12 months
Adults with chronic hepatitis B
CD4 cell rise
Within 5 days
Hospitalized COVID-19 patients on low-flow oxygen

Benefits

Contraindications
  • Organ or stem-cell transplant recipients on immunosuppression
  • Adults under 60 with sepsis
  • Pregnancy and breastfeeding
  • Active or poorly controlled autoimmune disease
  • Known hypersensitivity to thymosin alpha-1 or product excipients
    •
Key Interactions
  • Influenza vaccines
  • Immunosuppressants (tacrolimus, prednisone)
  • Immune checkpoint inhibitors (pembrolizumab, nivolumab)
    •
Theoretical (inferred from mechanism)
  • Over-the-counter fever and pain relievers (acetaminophen, ibuprofen)
  • Immune-stimulating supplements (echinacea, beta-glucans)
  • Other immune-active peptides (thymosin beta-4/TB-500, thymulin)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Injection-Site Reactions; Joint Pain, Hand Swelling and Rash; Serious Adverse Events; Liver Enzyme Flares in Hepatitis B; Possible Harm in Younger Adults With Sepsis
    •
  • Speculative: Impurities and Immunogenicity of Compounded or Gray-Market Product; Autoimmune Flares; Weakened Immunosuppression After Transplant
    •

Monitoring

Marker Target Why
Absolute lymphocyte count 1.0–4.8 × 10⁹/L Expected to change; also predicts response
CD4+ T-cell count and CD4/CD8 ratio CD4+ 500–1,500 cells/µL Expected to change
ALT 7–56 U/L Safety check: a flare stops or changes use
Hepatitis B surface antigen Negative Safety check: a positive result changes use
Vaccine-specific antibody titer No established target; rise from the individual's own pre-vaccination titer Expected to change

Cadence: Baseline before a first course; blood count and liver enzymes at 4 weeks, then every 3 months during continued use; vaccine antibody titer 4–6 weeks after vaccination; lymphocyte subsets 8–12 weeks after starting

Qualitative Assessment

  • Frequency and duration of colds, influenza-like illnesses and other infections
  • Recovery time after infections or vaccinations
  • Injection-site redness, swelling or pain
  • New joint pain, rashes or thyroid-related symptoms that could signal autoimmune activation
  • Energy levels and general sense of resilience during infection seasons
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.